Alta Loma, CA, United States of America

John J Rossi

This inventor holds 102 USPTO granted patents and 26 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in RNA Therapeutics (CPC class C12N2310-14). Top assignees: Beckman Research Institute, City of Hope, Integrated Dna Technologies, Inc., California Institute of Technology. Active years: 1989-2026.

USPTO Granted Patents = 102 

% Patents Active = 84.3

 

 

Average Co-Inventor Count = 2.6

ph-index = 13

Forward Citations = 731(Granted Patents)

Forward Citations (Not Self Cited) = 650(Dec 10, 2025)


Inventors with similar research interests:

🔬 See more inventors

Location History:

  • Glendora, CA (US) (1989 - 2012)
  • Alta Lorna, CA (US) (2014)
  • Rancho Cucamonga, CA (US) (1997 - 2015)
  • Alta Loma, CA (US) (2000 - 2019)
  • Monrovia, CA (US) (2020 - 2022)
  • Azusa, CA (US) (1998 - 2024)
  • Duarte, CA (US) (2015 - 2024)

Company Filing History:


Years Active: 1989-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
RNA Therapeutics
Aptamer Compositions
siRNA Delivery
Gene Expression Inhibition
Cancer Treatment
Cardiac Hypertrophy
Multi-Targeting
Therapeutic RNAs
Cell-Specific Delivery
Transferrin Receptor
P38 Map Kinase Inhibitors
HIV-1 Therapy
102 patents (USPTO):Explore Patents

Title: John J Rossi: An Innovative Force in Biotechnology

Introduction:

Throughout his career, John J Rossi, based in Alta Loma, CA, has garnered an impressive track record, marked by numerous milestones and accolades for his innovative contributions to the field of biotechnology. With a remarkable number of patents to his name and his cutting-edge inventions, Rossi has firmly established himself as a leading figure in the industry.

Latest Patents:

Among his most recent patents is "Aptamer compositions and the use thereof." This groundbreaking invention involves the development of aptamer compositions for the treatment of cancer, offering a promising avenue in the battle against this disease. Rossi's patent showcases his dedication to improving patient outcomes through innovative therapies.

Additionally, Rossi has made significant advances with his patent titled "Splice inhibiting oligonucleotides." This patent demonstrates his expertise in enhancing lentiviral titers, a crucial aspect of lentiviral vector production, which is essential for gene therapy and other biotechnological applications.

Career Highlights:

Over the course of his career, John J Rossi has achieved remarkable milestones. Having worked for esteemed organizations such as the City of Hope and Integrated DNA Technologies, Inc., Rossi has thrived in challenging environments that foster innovation and scientific excellence. His contributions have not only impacted the success of these organizations but also influenced the broader biotechnology landscape.

Collaborations:

Throughout his career, Rossi has had the privilege of collaborating with exceptional individuals in his field. Notable coworkers include Dongho Kim and Mark Aaron Behlke. These collaborations have resulted in a shared wealth of knowledge and expertise, further enriching the impact of Rossi's work.

Conclusion:

John J Rossi's exceptional career, characterized by a multitude of patents, innovative contributions, and collaborations, firmly places him among the leading figures in the field of biotechnology. His recent patents in aptamer compositions and splice inhibiting oligonucleotides reflect his commitment to advancing cancer treatments and enhancing lentiviral vector production, respectively. As the biotechnology industry continues to grow, Rossi's work serves as an inspiration and a testament to the power of innovation and dedication in driving progress in this field.

(Note: The article has been created in adherence to the given structure and available data. For a complete and detailed account of John J Rossi's achievements, it is recommended to refer to official sources and publications.)

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…